PRECISION BIOSCIENCES INC
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
DTIL$10.60+7.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share amounts)
(unaudited)
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $77,223 | $85,899 |
| Accounts receivable | 4 | 229 |
| Marketable securities | — | 413 |
| Prepaid expenses | 4,591 | 6,441 |
| Assets held for sale | 169 | 169 |
| Contract asset | — | 1,469 |
| Other current assets | 116 | 369 |
| Total current assets | 82,103 | 94,989 |
| Restricted cash | 22,566 | 22,569 |
| Property, equipment, and software—net | 2,717 | 3,089 |
| Intangible assets—net | 607 | 622 |
| Right-of-use assets—net | 6,780 | 7,090 |
| Investment in equity securities | 3,206 | 3,206 |
| Note receivable—net | 6,217 | 4,602 |
| Other assets | 215 | 221 |
| Total assets | $124,411 | $136,388 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $924 | $1,312 |
| Accrued compensation | 1,285 | 5,182 |
| Accrued research and development expenses | 1,307 | 2,016 |
| Deferred revenue | 5,731 | 2,957 |
| Lease liabilities | 1,365 | 1,320 |
| Other current liabilities | 896 | 989 |
| Current liabilities of discontinued operations | 885 | 1,204 |
| Total current liabilities | 12,393 | 14,980 |
| Loan payable | 22,337 | 22,321 |
| Deferred revenue | 20,501 | 23,300 |
| Lease liabilities | 6,046 | 6,404 |
| Warrant liability | 3,600 | 2,796 |
| Contract liabilities | 10,000 | 10,000 |
| Other noncurrent liabilities | 197 | 194 |
| Total liabilities | 75,074 | 79,995 |
| Stockholders’ equity: | ||
| Preferred stock: $0.0001 par value— 10,000,000 shares authorized as of March 31, 2025 and December 31, 2024; no shares issued and outstanding as of March 31, 2025 and December 31, 2024 | — | — |
| Common stock: $0.000005 par value— 200,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 10,575,867 shares issued and 10,548,852 shares outstanding as of March 31, 2025; 8,229,730 shares issued and 8,202,715 shares outstanding as of December 31, 2024 | 1 | 1 |
| Additional paid-in capital | 553,317 | 539,808 |
| Accumulated deficit | (503,029) | (482,464) |
| Treasury stock | (952) | (952) |
| Total stockholders’ equity | 49,337 | 56,393 |
| Total liabilities and stockholders’ equity | $124,411 | $136,388 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.